Switch theme
Sign up to access all valuation multiples
Xtant Medical Holdings Inc is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. The company's biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect Plus DBM putty, OsteoWrap, and the line of 3Demin products, as well as other allografts. It generates a majority of its revenue from the U.S.
2006
232
LTM Revenue $122M
LTM EBITDA $3.8M
$121M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Xtant Medical has a last 12-month revenue (LTM) of $122M and a last 12-month EBITDA of $3.8M.
In the most recent fiscal year, Xtant Medical achieved revenue of $117M and an EBITDA of -$7.9M.
Xtant Medical expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Xtant Medical valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $122M | XXX | $117M | XXX | XXX | XXX |
| Gross Profit | $73.3M | XXX | $68.2M | XXX | XXX | XXX |
| Gross Margin | 60% | XXX | 58% | XXX | XXX | XXX |
| EBITDA | $3.8M | XXX | -$7.9M | XXX | XXX | XXX |
| EBITDA Margin | 3% | XXX | -7% | XXX | XXX | XXX |
| EBIT | -$6.7M | XXX | -$12.1M | XXX | XXX | XXX |
| EBIT Margin | -5% | XXX | -10% | XXX | XXX | XXX |
| Net Profit | -$10.9M | XXX | -$16.4M | XXX | XXX | XXX |
| Net Margin | -9% | XXX | -14% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $28.0M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Xtant Medical's stock price is $1.
Xtant Medical has current market cap of $92.0M, and EV of $121M.
See Xtant Medical trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $121M | $92.0M | XXX | XXX | XXX | XXX | $-0.08 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Xtant Medical has market cap of $92.0M and EV of $121M.
Xtant Medical's trades at 1.0x EV/Revenue multiple, and -15.4x EV/EBITDA.
Equity research analysts estimate Xtant Medical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Xtant Medical has a P/E ratio of -8.4x.
See valuation multiples for Xtant Medical and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $92.0M | XXX | $92.0M | XXX | XXX | XXX |
| EV (current) | $121M | XXX | $121M | XXX | XXX | XXX |
| EV/Revenue | 1.0x | XXX | 1.0x | XXX | XXX | XXX |
| EV/EBITDA | 32.1x | XXX | -15.4x | XXX | XXX | XXX |
| EV/EBIT | -18.2x | XXX | -10.0x | XXX | XXX | XXX |
| EV/Gross Profit | 1.7x | XXX | n/a | XXX | XXX | XXX |
| P/E | -8.4x | XXX | -5.6x | XXX | XXX | XXX |
| EV/FCF | -14.9x | XXX | -7.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialXtant Medical's last 12 month revenue growth is 8%
Xtant Medical's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.3M for the same period.
Xtant Medical's rule of 40 is 14% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Xtant Medical's rule of X is 24% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Xtant Medical and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 8% | XXX | 8% | XXX | XXX | XXX |
| EBITDA Margin | 3% | XXX | -7% | XXX | XXX | XXX |
| EBITDA Growth | 157% | XXX | 26% | XXX | XXX | XXX |
| Rule of 40 | 14% | XXX | 2% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 24% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 42% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 2% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 68% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Xtant Medical acquired XXX companies to date.
Last acquisition by Xtant Medical was XXXXXXXX, XXXXX XXXXX XXXXXX . Xtant Medical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Xtant Medical founded? | Xtant Medical was founded in 2006. |
| Where is Xtant Medical headquartered? | Xtant Medical is headquartered in United States of America. |
| How many employees does Xtant Medical have? | As of today, Xtant Medical has 232 employees. |
| Who is the CEO of Xtant Medical? | Xtant Medical's CEO is Mr. Sean E. Browne. |
| Is Xtant Medical publicy listed? | Yes, Xtant Medical is a public company listed on ASE. |
| What is the stock symbol of Xtant Medical? | Xtant Medical trades under XTNT ticker. |
| When did Xtant Medical go public? | Xtant Medical went public in 2007. |
| Who are competitors of Xtant Medical? | Similar companies to Xtant Medical include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Xtant Medical? | Xtant Medical's current market cap is $92.0M |
| What is the current revenue of Xtant Medical? | Xtant Medical's last 12 months revenue is $122M. |
| What is the current revenue growth of Xtant Medical? | Xtant Medical revenue growth (NTM/LTM) is 8%. |
| What is the current EV/Revenue multiple of Xtant Medical? | Current revenue multiple of Xtant Medical is 1.0x. |
| Is Xtant Medical profitable? | Yes, Xtant Medical is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Xtant Medical? | Xtant Medical's last 12 months EBITDA is $3.8M. |
| What is Xtant Medical's EBITDA margin? | Xtant Medical's last 12 months EBITDA margin is 3%. |
| What is the current EV/EBITDA multiple of Xtant Medical? | Current EBITDA multiple of Xtant Medical is 32.1x. |
| What is the current FCF of Xtant Medical? | Xtant Medical's last 12 months FCF is -$8.1M. |
| What is Xtant Medical's FCF margin? | Xtant Medical's last 12 months FCF margin is -7%. |
| What is the current EV/FCF multiple of Xtant Medical? | Current FCF multiple of Xtant Medical is -14.9x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
